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Vascular calcification is a life-threatening clinical condition in chronic kidney disease
(CKD) and is associated with reduced zinc serum levels. Anemia is another frequent
complication of CKD. Hypoxia-inducible factor (HIF) stabilizers, also known as HIF
prolyl hydroxylase inhibitors (PHI), are promising candidates to treat CKD-associated
anemia by increasing erythropoietin synthesis. Recent evidence suggests that HIFs
play a pivotal role in vascular calcification. Our study explored feasible impacts of
HIF PHI on phosphate (Pi)-induced calcification of vascular smooth muscle cells
(VSMCs) and tested whether zinc might inhibit this mineralization process. Treatment
of VSMCs with PHI aggravated Pi-induced calcium deposition and Pi uptake. PHI
promoted Pi-induced loss of smooth muscle cell markers (ACTA-2, MYH11, SM22α)
and enhanced osteochondrogenic gene expression (Msx-2, BMP-2, Sp7) triggering
osteochondrogenic phenotypic switch of VSMCs. These effects of PHI paralleled
with increased pyruvate dehydrogenase kinase 4 (PDK4) expression, decreased
Runx2 Ser451 phosphorylation, and reduced cell viability. Zinc inhibited Pi-induced
mineralization of VSMCs in a dose-dependent manner and also attenuated the pro-
calcification effect of PHI in Pi-induced mineralization. Zinc inhibited osteochondrogenic
phenotypic switch of VSMCs reflected by lowering Pi uptake, decreasing the
expressions of Msx-2, BMP-2, and Sp7 as well as the loss of smooth muscle cell-
specific markers. Zinc preserved phosphorylation state of Runx2 Ser451, decreased
PDK4 level, and restored cell viability. PHI alone reduced the expression of smooth
muscle markers without inducing mineralization, which was also inhibited by zinc.
In addition, we observed a significantly lower serum zinc level in CKD as well
as in patients undergoing carotid endarterectomy compared to healthy individuals.
Conclusion - PHI promoted the loss of smooth muscle markers and augmented
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Pi-induced osteochondrogenic phenotypic switch leading to VSMCs calcification.
This mineralization process was attenuated by zinc. Enhanced vascular calcification is a
potential risk factor during PHI therapy in CKD which necessitates the strict follow up of
vascular calcification and zinc supplementation.
Keywords: VSMC, vascular calcification, phosphate, Zn supplementation, Pi, prolyl hydroxylase inhibitor
INTRODUCTION
Anemia is a clinical hallmark of chronic kidney disease (CKD)
representing a worldwide burden on public health (Levey
et al., 2007; Webster et al., 2017) by reducing the quality of life
and increasing cardiovascular disease and mortality (KDOQI
and National Kidney Foundation, 2006). One of the main
characteristics of systemic vascular pathology in chronic renal
failure is the accelerated vessel wall calcification (Palit and
Kendrick, 2014). There is a continuous and innovative evolution
in the treatment of CKD-associated anemia, but preventive
and therapeutic interventions against vascular calcification are
still limited. A promising approach to correct CKD-associated
anemia is the pharmacologic inhibition of hypoxia-inducible
factor (HIF) prolyl-4-hydroxylase domain (PHD) proteins.
HIFs regulate multiple genes, including erythropoietin (EPO)
and EPO receptor, and proteins promoting iron absorption,
iron transport (transferrin), and heme synthesis (Peyssonnaux
et al., 2007; Kaelin and Ratcliffe, 2008). Hydroxylation of
HIFs is performed by three PHD proteins PHD1, PHD2, and
PHD3 (Schofield and Ratcliffe, 2004). Under normoxia, PHD
proteins hydroxylate HIFs facilitating their polyubiquitination
and proteasomal degradation, thereby inhibiting the activation
of HIF-responsive genes (Fong and Takeda, 2008). Thus,
pharmacological inactivation of PHD enzymes stimulates
endogenous EPO production both in animals and humans
(Hsieh et al., 2007; Bernhardt et al., 2010). FG4592 is one of
the orally bioavailable HIF PHD inhibitors (PHI) promoting
erythropoiesis through an HIF-dependent manner. Clinical
trials have demonstrated that PHI FG4592 effectively corrects
anemia in CKD patients (Besarab et al., 2015, 2016; Provenzano
et al., 2016; Chen et al., 2017), therefore, together with other
HIF PHIs, has gained attention as a promising alternative for
erythropoiesis-stimulating agents (Gupta and Wish, 2017).
Chronic kidney disease and end-stage kidney disease are
associated with increased cardiovascular mortality and morbidity
(Sigrist et al., 2007; Collins et al., 2015). In CKD, the prevalence
of vascular calcification is high and appears at a younger age
compared to the healthy population (Goodman et al., 2000).
Hyperphosphatemia is closely associated with advanced vascular
calcification (Shigematsu et al., 2003; Adeney et al., 2009) and
increases mortality in CKD (Kestenbaum et al., 2005). Clinical
drugs against vessel wall calcification are still not available,
but research effort is significant in exploring this field. It is
documented that plasma zinc levels are low in dialysis patients
and zinc supplementation has been shown to attenuate high
phosphate induced calcification and osteoblastic transformation
of VSMC (Shin and Kwun, 2014; Voelkl et al., 2018).
Recent evidence suggests that HIFs play a pivotal role in
vascular calcification (Mokas et al., 2016; Zhu et al., 2018). It is
uncovered whether HIF stabilizer PHIs have any effect on the
mineralization of VSMC. PHI FG4592, one of the promising
PHIs, prompted us to explore the influence of PHI FG4592 on
vessel calcification using an in vitro approach. Since the level
of plasma zinc is low in CKD, we sought to investigate the
relationship between PHIs and zinc in vascular calcification.
In this study, we provide evidence that PHI FG4592 facilitates
phosphate induced calcification in VSMC, which is attenuated by
zinc supplementations.
MATERIALS AND METHODS
Reagents
All reagents were purchased from Sigma-Aldrich (St. Louis, MO,
United States) unless otherwise stated.
Cell Culture
Human aortic smooth muscle cells (VSMCs) were purchased
from Cell Applications (San Diego, CA, United States, Cat.: 354-
05a) and Lonza (Allendale, NJ, United States Cat.: CC-2571). Zinc
dose experiments were performed on cells purchased from Cell
Applications, while all the other experiments were performed on
VSMCs purchased from Lonza. Cells were grown in Dulbecco’s
Modified Eagle Medium (DMEM) containing 1000 mg/L glucose
supplemented with 10% fetal bovine serum (Life Technologies,
Vienna, Austria), 100 U/ml penicillin, 100 µg/ml streptomycin,
and neomycin referring to as growth medium (GM). Cells were
grown to confluence and used from passages 5 to 7. Media
were changed every 2 days. To induce phosphate mediated
calcification, GM was supplemented with inorganic phosphate
(3 mmol/L referring to as calcification medium) in a form
of Na2HPO4/NaH2PO4 (pH 7.4) in the presence or absence
of zinc (15–30 µmol/L of ZnCl2 × 6H2O) for 10 days. To
investigate the effect of PHI FG4592 on VSMC calcification, cells
were treated with FG4592 (Selleckchem, Houston, United States)
in various concentrations (5 and 20 µmol/L) in calcification
medium in the presence or absence of zinc (30 µmol/L) for
3, 6 or 10 days.
Human Samples
Healthy volunteers were recruited without any known diseases
including hypertension, dyslipidemia, liver and kidney
malfunctions (n = 18, mean age 46 years, F/M 7/11). Stage
5 CKD patients subjected to hemodialysis were selected (n = 28,
mean age 55 years, F/M 15/13) from the dialysis unit of the
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Clinical Centre, Department of Internal Medicine, University
of Debrecen, Debrecen, Hungary. Vascular disease group was
selected from patients undergoing carotid endarterectomy
(n = 15, mean age 72 years, F/M 6/9). Volunteers did not take
any zinc supplementation. Blood was drawn in Vacutainers (BD,
Franklin Lakes, NJ, United States) using citrate immediately
before surgery or the hemodialysis session from CKD patients
by venipuncture. Participants gave their informed consent to
the study, which was approved by the Regional and Institutional
Ethics Committee of the University of Debrecen, Medical and
Health Science Center. All subjects gave written informed
consent in accordance with the Declaration of Helsinki.
Measurement of Plasma Zinc
Concentration With Inductively Coupled
Plasma-Atomic Emission Spectrometry
(ICP-AES)
A five milliliters serum samples were digested two times with
10 – 10 ml Carlo Elba nitric acid 65% (m/m) on water-bath
at atmospheric conditions. The digestion was finished with
2 – 2 ml analytical grade hydrogen peroxide 30% (m/m) (Reanal,
Hungary). The digested samples were filled to 10 ml with
deionized water. At the same time with these sample digestion, we
prepared blank solutions from nitric acid and hydrogen peroxide,
too. Flame atomic absorption spectrometric (FAAS) analysis was
carried out using the following settings. Hollow cathode lamp: Zn
Cathodeon lamp, Lamp current: 10 mA, Wavelength: 213.9 nm,
Slot burner: 10 cm, Acetylene: 1 L/min, Air: 5 L/min (3 bar),
Observation height: 10 mm. The zinc concentrations are the
average of three parallel measurements.
Alizarin Red Staining
Cells were washed with phosphate-buffered saline (PBS) pH 7.4
without Ca2+ and Mg2+ and fixed with 4% paraformaldehyde
for 10 min at room temperature. Then, cells were rinsed with
PBS without Ca2+ and Mg2+ and stained with 2% Alizarin
Red S for 10 min. Excessive dye was removed by several
washes in deionized water. Extracellular calcium deposition was
stained in red color.
Quantification of Calcium Deposition
Cells grown on 24-well plates were washed twice with PBS pH
7.4 without Ca2+ and Mg2+ and decalcified with 0.6 mol/L HCl
for 30 min at 37◦C. After decalcification, cells were solubilized
with a solution of NaOH 0.1 mol/L and SDS 0.1%, and the
protein content of samples was measured with bicinchoninic acid
(BCA) protein assay kit (Pierce, Rockford, IL, United States).
The calcium content of the cells was normalized to protein
content and expressed as µg/mg protein. The calcium content of
the supernatants was determined by the QuantiChrom Calcium
Assay Kit (Gentaur, Brussels, Belgium).
Measurement of Intracellular Inorganic
Phosphate
Intracellular inorganic phosphate concentration was determined
by colorimetric analysis using QuantiChromTM Phosphate Assay
Kit (Gentaur). Cells were washed twice with PBS pH 7.4
without Ca2+ and Mg2+ and then lysed with solubilization
buffer (1% Triton-X 100, 0.5% Igepal CA-630, 10% protease
inhibitor. 150 mmol/L NaCl, 5 mmol/L EDTA, 10 mmol/L Tris).
Intracellular phosphate concentration of the cells was normalized
to protein content expressed as µmol/mg protein.
RNA Isolation and Quantitative Reverse
Transcription – Polymerase Chain
Reaction
Vascular smooth muscle cells were grown on 24-well plates
and total RNA was isolated using TRIzol (Invitrogen, Carlsbad,
CA, United States). The cDNA was synthesized using a
High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA, United States) for RT-PCR.
Real-time polymerase chain reactions were performed using
fluorescent TaqMan probes. TaqMan gene expression assays
for BMP-2 (Hs00154192_m1), Msx-2 (Hs00741177_m1),
PDK-4 (Hs01037712_m1), TAGLN/SM22α (Hs0103877_g1),
smooth muscle α-actin/ACTA2 (Hs00426895_g1, MYH11
(Hs00975796_m1), Sp7 (Hs01866874_s1), and RNA45S5
(Hs05627131_gH) were purchased from Thermo Scientific,
United States. Gene expressions were normalized to RNA45S5
(Hs05627131_gH). Polymerase chain reactions were carried out
using the iCycler iQ Real-Time PCR system (Bio-Rad, Hercules,
CA, United States) and the results represent the relative mRNA
expression of target genes normalized RNA45S5 mRNA levels.
Preparation of Whole-Cell Lysates and
Nuclear Fractions
To prepare whole cell lysates, VSMCs were washed with PBS
pH 7.4 without Ca2+ and Mg2+ then lysed using RIPA buffer
(50 mmol/L Tris [pH 7.5], 150 mmol/L NaCl, 1% Igepal
CA-630, 1% sodium deoxycholate, 0,1% SDS) containing 10%
Complete Mini Protease Inhibitor Cocktail and 20% PhosSTOP
phosphatase inhibitor cocktail, and incubated for 20 min on
ice. Lysates were centrifuged at 14,000 × g, 4◦C for 20 min.
Supernatants were used as whole-cell extracts.
For nuclear fraction separation, cells were washed with
PBS pH 7.4 without Ca2+ and Mg2+ then scraped with
ice-cold hypotonic buffer (20 mmol/L HEPES, 250 mmol/L
Sucrose, 10 mmol/L KCl, 2 mmol/L MgCl2) containing 10%
Complete Mini Protease Inhibitor Cocktail and 20% PhosSTOP
phosphatase inhibitor cocktail on ice. Using 1 ml syringe, the
cell suspension was passed through a 28G needle 30 times
then swelled on ice for 20 min. Lysates were centrifuged at
15,000 × g, 4◦C for 15 min. Supernatants were discarded
and this procedure was repeated 4 times. Finally, the nuclear
pellets were dissolved in RIPA buffer supplemented with 10%
Complete Mini Protease Inhibitor Cocktail and 20% PhosSTOP
phosphatase inhibitor cocktail and centrifuged at 16,000 × g,
4◦C for 15 min. Supernatants were used as nuclear fractions.
Protein content was determined using the bicinchoninic acid
assay (Pierce BCA Protein Assay Kit, Thermo Fisher Scientific,
Waltham, MA, United States).
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Immunoblotting
Cell extracts (25–30 µg protein) were electrophoresed on 10
or 12% Tris–glycine SDS-gels and proteins were transferred
to 0.22 µm PVDF membrane (Advansta Inc., Menlo Park,
CA, United States). Membranes were blocked with 5% w/v
milk for 60 min at room temperature. After blocking,
membranes were incubated with Runx-2 antibody (Cell Signaling
Technology, Danvers, MA, United States, Cat.: 12556) at 1:1000
dilution, Runx-2 (Ser 451) antibody (Bioss Antibodies Inc.,
Woburn, MA, United States, Cat.: bs-5685R) at 1:500 dilution,
metallothionein (Abcam, Cambridge, United Kingdom; Cat.:
# ab12228) 1:1000, and PDK-4 (Abcam, Cat.: ab88063) at 1:1000
dilution. Antigen-antibody complexes were visualized with the
horseradish peroxidase chemiluminescence system (Advansta,
Menlo Park, CA, United States). Protein bands were normalized
to Hsp90 (Cell Signaling; Cat.: 4874S and Lamin B1 (Proteintech,
Manchester, United Kingdom, Cat: 66095-I-Ig).
MTT Assay
Cell viability was determined by the MTT assay. Briefly, cells were
cultured and treated in 96-well plates for the indicated time. Then
cells were washed with PBS, and 100µl of 3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyl-tetrazolium bromide (0.5 mg/ml) solution
in HBSS was added. After a 90-minute incubation, the MTT
solution was removed, formazan crystals were dissolved in
100 µL of DMSO and optical density was measured at 570 nm.
MT1a and MT2a siRNA Transfection
Small interfering RNA specific to MT1a (Cat.: 4392420; ID:
s194620) and MT2a (Cat.: 4392420; ID: s194629) and negative
control siRNA (Cat.: 4390843) were obtained from Ambion
(Thermo Scientific, Waltham, MA, United States). Transfection
of siRNA into VSMCs was performed using Oligofectamine
reagent (Thermo Scientific, Waltham, MA, United States)
according to the manufacturer’s guide. Briefly, the cells were
plated on 24-well plates to form 60–70% confluent monolayers.
MT1a and MT2a siRNA were applied at 20 pmol/L concentration
and transfection reagent complex were added to the cells for 5 h
in OPTI-MEM Reduced Serum Medium then replaced to the
growth medium for 16 h then to calcification or normal growth
medium until the next transfection procedure. This transfection
protocol was repeated every 3 days. Gene expression of MTs was
analyzed by q-RT-PCR and immunoblot after 10 days.
Statistical Analysis
Data are shown as mean ± SEM. Statistical analysis was
performed by one-way ANOVA test followed by Bonferroni
correction. A value of p< 0.05 was considered significant.
RESULTS
Zinc Inhibits Phosphate-Induced
Mineralization of VSMCs in a
Dose-Dependent Manner
Zinc has been shown to prevent phosphate (Pi)-
induced osteogenic trans-differentiation of VSMCs
(Shin and Kwun, 2014, 2016). To examine whether zinc inhibits
Pi-provoked mineralization of VSMCs in our experimental
conditions, we cultured human VSMCs in calcification
medium containing 3 mmol/L inorganic Pi in the presence
(15–30 µmol/L) or absence of zinc for 10 days (Figures 1A–C).
Granular deposits were examined by Alizarin Red Staining
which revealed that Pi significantly promoted mineral deposition
compared to the untreated cells, while the exposure of VSMCs
to zinc dose-dependently decreased Pi-induced mineralization
(Figure 1A) and significantly decreased extracellular matrix
(ECM) calcium content (Figure 1B). Active uptake of Pi into the
cells via the type III sodium-dependent phosphate cotransporter,
Pit-1, is a key factor of Pi-induced calcification of VSMCs (Li
et al., 2006). Therefore, we measured Pi uptake by analyzing
intracellular Pi levels in calcification medium in the presence
or absence of zinc. Pi induced a robust increase in intracellular
Pi compared to untreated cells, while at a concentration of
15 µmol/L, zinc significantly lowered Pi uptake (Figure 2C).
Importantly, 30 µmol/L zinc decreased Pi content of VSMCs
exposed to high Pi down to the level of cells maintained in
growth medium (Figure 2C). Overall, these data demonstrate
that zinc effectively inhibits Pi-induced mineral deposition and
Pi uptake by human VSMCs in a dose-dependent manner.
PHI Enhances Pi-Induced Mineral
Deposition in VSMCs That Is Inhibited by
Zinc
Hypoxia greatly enhances VSMCs calcification and osteochon-
drogenic trans-differentiation (Mokas et al., 2016) which raises
the question whether stabilization of HIFs influences VSMCs
calcification. VSMCs cultured in calcification medium were
exposed to PHI FG4592 (5 and 20 µmol/L, respectively) in
the presence (30 µmol/L) or absence of zinc for 10 days, and
mineral deposition, the calcium content of ECM as well as Pi
uptake by VSMCs were analyzed (Figures 2A–C). We showed
that PHI markedly enhanced Pi-induced VSMC mineralization
compared to Pi alone, while zinc (30 µmol/L) inhibited enhanced
calcification by PHI (Figure 2A). To quantify the extent of
matrix mineralization, the calcium content of the ECM was
measured after 10 days. PHI increased the calcium content
of the ECM in a dose-dependent manner compared to Pi
alone, which was significantly attenuated when zinc (30 µmol/L)
was present in the experimental medium (Figure 2B). Similar
to ECM calcium content, PHI dose-dependently enhanced Pi
uptake and intracellular Pi levels compared to high Pi alone
that was markedly inhibited by zinc (Figure 2C). Overall, our
data presented here show that chemical stabilization of HIF by
PHI FG4592 strongly enhances Pi-induced mineralization and Pi
uptake by VSMC, and these processes are significantly attenuated
by zinc supplementation.
PHI Decreases Smooth Muscle-Specific
Marker Expression
Downregulation of smooth muscle-specific markers is a common
characteristic of VSMCs calcification (Steitz et al., 2001), and
recent evidence shows that HIF1α induces phenotypic switch in
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FIGURE 1 | Zinc inhibits phosphate induced mineralization of VSMCs in a dose-dependent manner. VSMCs were cultured in calcification medium containing
3 mmol/L phosphate (Pi) in the presence (15–30 µmol/L) or absence of zinc for 10 days (A–C). (A) Calcium deposition as a marker of ECM mineralization was
visualized by Alizarin Red staining. Representative wells and images of stained plates from three independent experiments are shown. Statistical analysis was
performed by one-way ANOVA test followed by Bonferroni correction. A value of p < 0.05 was considered significant. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. (B) The
calcium content of solubilized ECM is presented. Data are expressed as mean ± SEM of three independent experiments. Statistical analysis was performed by
one-way ANOVA test followed by Bonferroni correction. A value of p < 0.05 was considered significant. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. (C) Intracellular Pi
levels were determined from the cell lysates and results are presented as mean ± SEM of three independent experiments. Statistical analysis was performed by
one-way ANOVA test followed by Bonferroni correction. A value of p < 0.05 was considered significant. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Experiments were
performed on VSMCs purchased from Cell Applications.
VSMCs (Liu et al., 2017). Therefore, we examined whether PHI
aggravates Pi-induced loss of smooth muscle-specific markers
such as smooth muscle α-actin (ACTA-2), smooth muscle
myosin heavy chain 11 (MYH11), and smooth muscle protein
22α (TAGLN). VSMCs were cultured in growth medium in
the presence or absence of PHI (5 and 20 µmol/L) or in
calcification medium with or without PHI and zinc for 3, 6,
and 10 days. We showed that Pi induced the downregulation
of ACTA-2 (Figure 3A), MYH-11 (Figure 3B), and TAGLN
(Figure 3C) expression that was significantly aggravated by
PHI in a dose-dependent manner after 10 days. These results
support the hypothesis that high Pi and PHI synergistically
boost calcification of VSMCs. Interestingly, PHI also induced
a dose-dependent decrease in smooth muscle markers in
growth medium without high Pi (Figures 3A-C). Importantly,
zinc (30 µmol/L) significantly restored smooth muscle-specific
gene expression in response to Pi as well as to Pi + PHI
(Figures 3A–C). In addition, time-course experiments showed
that the increased loss of smooth muscle-specific markers in
response to PHI can be detected as early as 3 days, which is also
attenuated by zinc (Supplementary Figures 1A–F). Overall, these
data suggest that PHI downregulates smooth muscle-specific
markers independently of the Pi level, however, Pi and PHI
act synergistically to decrease smooth muscle-specific markers,
which is attenuated by zinc.
PHI Enhances the Expression of
Osteochondrogenic Markers That Is
Inhibited by Zinc
To decipher the molecular mechanism involved in PHI-enhanced
calcification of VSMCs induced by Pi, and to explore zinc’s
inhibitory effect on this process, a possible direct effect of
PHI on osteochondrogenic gene expressions of VSMCs were
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FIGURE 2 | Prolyl hydroxylase inhibitor (PHI) FG4592 enhances Pi-induced mineral deposition in VSMCs that is inhibited by zinc. VSMCs cultured in calcification
medium were treated with PHI FG4592 (5 and 20 µmol/L, respectively) in the presence (30 µmol/L) or absence of zinc for 10 days (A–C). (A) Calcium deposition as
a marker of ECM mineralization was visualized by Alizarin Red staining. Representative wells and images of stained plates from three independent experiments are
shown. Statistical analysis was performed by one-way ANOVA test followed by Bonferroni correction. A value of p < 0.05 was considered significant. ∗p < 0.05,
∗∗p < 0.01, ∗∗∗p < 0.001. (B) The calcium content of solubilized ECM is presented. Data are expressed as mean ± SEM of three independent experiments.
Statistical analysis was performed by one-way ANOVA test followed by Bonferroni correction. A value of p < 0.05 was considered significant. ∗p < 0.05, ∗∗p < 0.01,
∗∗∗p < 0.001. (C) Intracellular Pi levels were determined from the cell lysates and results are presented as mean ± SEM of three independent experiments.
Statistical analysis was performed by one-way ANOVA test followed by Bonferroni correction. A value of p < 0.05 was considered significant. ∗p < 0.05, ∗∗p < 0.01,
∗∗∗p < 0.001.
investigated in time-course experiments (Figures 4A–C and
Supplementary Figures 2A–F). High Pi increased BMP-2, Msx-2
as well as Sp7 expression after 10 days that was aggravated by
PHI (Figures 4A–C). These effects were significantly reduced
by zinc supplementation. Importantly, PHI did not influence
osteochondrogenic gene expression without high Pi level even
after 10 days (Figures 4A–C). We showed that neither high Pi nor
PHI and high Pi+ PHI induced BMP-2 and Msx-2 expression as
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FIGURE 3 | Continued
FIGURE 3 | Prolyl hydroxylase inhibitor (PHI) FG4592 decreases smooth
muscle marker expression that is prevented by zinc. VSMCs were cultured in
growth medium in the presence or absence of PHI (5 and 20 µmol/L) or in
calcification medium with or without PHI FG4592 and zinc for 10 days, and
the expression of smooth muscle-specific markers were measured using
qRT-PCR (A–C). (A) Relative expression of ACTA-2 (smooth muscle alpha
(α)-2 actin), (B) MYH11 (smooth muscle myosin heavy chain 11), and (C)
TAGLN (smooth muscle protein 22-α) were determined by qRT-PCR and
normalized to RNA45S5. Results are presented as mean ± SEM of three
independent experiments. Statistical analysis was performed by one-way
ANOVA test followed by Bonferroni correction. A value of p < 0.05 was
considered significant. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
early as 3 or 6 days (Supplementary Figures 2A–D), and only Sp7
gene expression was elevated at 6 days in response to Pi + PHI
(20 µmol/L), which was ameliorated by zinc. Taken together, PHI
aggravated osteochondrogenic gene expression induced by high
Pi, which was ameliorated by zinc.
PHI Influences Ser451 Phosphorylation
of Runx2 and Induces Pyruvate
Dehydrogenase Kinase 4 Expression
Runx2-dependent transactivation of osteochondrogenic genes
is greatly influenced by the phosphorylation of its serine
residues (Wee et al., 2002; Ge et al., 2009; Li et al., 2017).
To gain further insight into the mechanism by which zinc
inhibits Pi and Pi + PHI mediated calcification of VSMC,
we analyzed the nuclear translocation and phosphorylation of
Runx2 Ser451 in nuclear extracts derived from cells treated
with Pi and Pi + PHI in the presence or absence of zinc
(Figures 5A,B and Supplementary Figures 3A,B). As a result,
we showed that the nuclear translocation of Runx2 was not
affected either by Pi or Pi + PHI after 10 days (Figure 5A).
We next explored whether Pi or PHI + Pi influences Ser451
phosphorylation after 3, 6, and 10 days. The phosphorylation
level of Runx2 Ser451 was unaltered in cells exposed to high
Pi alone at all time points but was significantly reduced after
6 and 10 days when PHI was also present in the calcification
medium (Figure 5B and Supplementary Figure 3B). The
phosphorylation of Runx2 Ser451 was unaltered after 3 days
in response to high Pi + PHI (Supplementary Figure 3A).
Importantly, zinc restores the phosphorylation level of Ser451
in response to high Pi + PHI after 6 and 10 days of treatments
(Figure 5B and Supplementary Figure 3B).
Pyruvate dehydrogenase kinase 4 plays an important role in
vascular calcification (Lee et al., 2015; Zhu et al., 2018). We next
explored whether PDK4 is involved in the enhanced calcification
triggered by PHI in calcification medium (Figures 5C,D). Pi
alone led an about 3-fold induction in PDK4 mRNA measured
by reverse transcription qPCR after 10 days which was further
increased by PHI in a dose-dependent fashion (Figure 5C).
Elevated PDK4 mRNA levels were significantly attenuated when
zinc (30 µmol/L) was added to the Pi medium with or without
PHI (Figure 6C). Consistent with these findings, PDK4 protein
levels were also increased by PHI which was also mitigated by zinc
(Figure 5D). These data demonstrate that both transcriptional
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FIGURE 4 | Continued
FIGURE 4 | Prolyl hydroxylase inhibitor (PHI) FG4592 enhances the
expression of osteochondrogenic markers that is inhibited by zinc. VSMCs
were cultured in growth medium in the presence or absence of PHI FG4592 (5
and 20 µmol/L) or in calcification medium with or without PHI and zinc for
10 days, and the expression of osteochondrogenic markers was measured
using qRT-PCR (A–C). (A) Relative expression of BMP-2 (bone morphogenic
protein-2), (B) Msx-2 (Msh Homeobox 2), and (C) SP7 were determined by
qRT-PCR and normalized to RNA45S5. Results are presented as
mean ± SEM of three independent experiments. Statistical analysis was
performed by one-way ANOVA test followed by Bonferroni correction. A value
of p < 0.05 was considered significant. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
and post-translational effects of PHI on VSMC calcification can
be counteracted by zinc.
Zinc Restores the Viability of VSMCs in
Response to High Pi and PHI
It has been reported that zinc improves cell viability during
VSMCs calcification (Shin and Kwun, 2014). To explore the
involvement of cell death in PHI-aggravated calcification, VSMCs
were treated with PHI in growth medium alone and or in
calcification medium in the presence or absence of PHI and zinc
for 3, 6, and 10 days. As illustrated in Figure 6, neither high
Pi nor PHI and Pi + PHI affected cell viability after 3 days
(Figure 6A). However, after 6 days, PHI decreased cell viability
independently of the presence of Pi that was not affected by zinc
(Figure 6B). After 10 days, cell viability was decreased in response
to high Pi, which was aggravated by PHI (Figure 6C). Similar
to the 6-day-treatments, PHI induced cell death regardless the
Pi level in the experimental medium. In contrast to the 6-day-
experiments, zinc restored cell viability after 10 days (Figure 6C).
Thus, zinc prevents the decrease in cell viability in response to
Pi+ PHI only in the late phase of the experiments.
Inhibitory Effect of Zinc Is Independent
of Zinc-Responsive Protein
Metallothionein
Metallothioneins (MTs) are abundantly induced by a high
amount of zinc and cadmium (Hamer, 1986) and characterized
by potent antioxidant properties (Viarengo et al., 2000).
Since reactive oxygen species (ROS) and oxidative stress are
linked to vascular calcification (Scholze et al., 2016), next we
examined whether zinc inhibits Pi provoked mineralization of
VSMC in an MT-dependent fashion. VSMC were cultured in
calcification medium containing 3 mmol/L Pi in the presence
(30 µmol/L), or absence of zinc for 10 days and MT1/MT2
gene expressions were analyzed by qRT-PCR. Our results showed
that exposure of cells to zinc (30 µmol/L), slightly above the
physiological concentration, did not induce MT1a and MT2a
in our experimental conditions compared to untreated cells
(Data not shown).
Metallothioneins have been shown to be expressed in
atherosclerotic plaques representing a local protective
mechanism (Göbel et al., 2000; Daskalopoulou et al., 2007).
This prompted us to examine whether MT expression provoked
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FIGURE 5 | Prolyl hydroxylase inhibitor (PHI) FG4592 influences Ser451 phosphorylation of Runx2 and induces pyruvate dehydrogenase kinase 4 expression VSMC
cultured in calcification medium were treated with PHI FG4592 (5 and 20 µmol/L, respectively) in the presence (30 µmol/L) or absence of zinc for 10 days (A–D).
(A) Nuclear translocation and (B) Ser451 phosphorylation of Runx2 were analyzed by immunoblot of nuclear extracts followed by the densitometric analyses of blots
from three independent experiments. Results are presented as mean ± SEM of three independent experiments normalized to Lamin B1. Statistical analysis was
performed by one-way ANOVA test followed by Bonferroni correction. A value of p < 0.05 was considered significant. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Blots
show one representative image from three independent experiments. (C) The expression of PDK4 was analyzed by qRT-PCR and normalized to RNA45S5. Results
are presented as mean ± SEM of three independent experiments. Statistical analysis was performed by one-way ANOVA test followed by Bonferroni correction.
A value of p < 0.05 was considered significant. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. (D) The expression of PDK4 was analyzed by immunoblot and normalized to
Hsp90. Results are presented as mean ± SEM of three independent experiments normalized to Lamin B1. Statistical analysis was performed by one-way ANOVA
test followed by Bonferroni correction. A value of p < 0.05 was considered significant. ∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗p < 0.001. Blots show one representative image
from three independent experiments.
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FIGURE 6 | Zinc restores the viability of VSMCs in response to high
Pi and PHI FG4592. VSMCs were cultured in growth medium in the presence or
(Continued)
FIGURE 6 | Continued
absence of PHI FG4592 (5 and 20 µmol/L) or in calcification medium with or
without PHI FG4592 and zinc for 3, 6, and 10 days. (A–C). Cell viability was
determined by MTT assay after (A) 3, (B) 6, and (C) 10 days. Statistical
analysis was performed by one-way ANOVA test followed by Bonferroni
correction. A value of p < 0.05 was considered significant. ∗p < 0.05,
∗∗p < 0.01, ∗∗∗p < 0.001.
by supraphysiological zinc concentration (100 µmol/L), seven-
time higher than the normal plasma level, inhibits calcification
of VSMC in vitro. Zinc (100 µmol/L) markedly increased the
expression of MT1a/2a compared to either the untreated VSMCs
or cells cultured in the calcification medium (Figure 7A). To
explore the role of MT1a/2a on VSMC mineralization in this
calcification model, MT1a/2a expression was silenced with
MT1/2 specific siRNAs. Q-RT-PCR and immunoblot analysis of
VSMC demonstrated that siRNA treatment effectively decreased
MT1/2 expression in cells exposed to zinc (100 µmol/L)
(Figure 7B). Interestingly, ECM calcium deposition was not
affected by MT1a/2a levels, since zinc inhibited Pi induced
calcium deposition despite suppressed MT1a/2a expression
(Figures 7C,D). This observation suggests that the inhibitory
effect of zinc on Pi induced mineralization is independent MT.
Plasma Zinc Level Is Reduced in Patients
Undergoing Carotid Endarterectomy and
in CKD Patients on Hemodialysis
A recent report revealed that reduced zinc levels in CKD
contribute to the severity of vascular calcification (Voelkl et al.,
2018), however, the possible link between plasma zinc level
and progression of vascular disease in patients with physiologic
kidney function has not been established. Therefore, we asked
whether low zinc plasma concentration is associated with
vascular disease in patients diagnosed with significant carotid
artery stenosis undergoing carotid endarterectomy. Plasma zinc
levels were measured with inductively coupled plasma-atomic
emission spectrometry (ICP-AES) in patients with intact kidney
function undergoing carotid surgery and compared to CKD
patients on hemodialysis and healthy controls (Figure 8).
According to previous studies, plasma zinc levels were reduced
in CKD patients compared to healthy subjects. Importantly,
plasma zinc levels of patients with carotid artery stenosis were
significantly reduced compared to healthy controls. These data
suggest that low plasma zinc concentration is a potential risk
factor for vascular diseases of different etiology.
DISCUSSION
The results of this study demonstrate that HIF PHI aggravates
high Pi-induced osteochondrogenic transformation and
mineralization of VSMCs, which is inhibited by zinc
supplementation. Our data highlight several key findings:
(1) PHI FG4592 induces the loss of SMC-specific markers
but does not trigger osteochondrogenic marker expression
alone at physiologic Pi level; (2) PHI FG4592 aggravates high
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FIGURE 7 | Inhibitory effect of zinc is independent of zinc-responsive protein metallothionein. VSMCs were cultured in calcification medium containing 3 mmol/L Pi in
the presence (100 µmol/L), or absence of zinc for 10 days (A,B). Relative expression of methallothionenin 1A (A) and 2A (B) were determined by qRT-PCR and
normalized to RNA45S5. Results are presented as mean ± SEM of three independent experiments. Statistical analysis was performed by one-way ANOVA test
followed by Bonferroni correction. A value of p < 0.05 was considered significant. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. VSMCs were transfected with MT1a/2A
siRNA and cultured in calcification medium containing 3 mmol/L Pi in the presence (100 µmol/L), or absence of zinc for 10 days. Gene expression of MTs was
analyzed by q-RT-PCR and immunoblot after 10 days. (C,D). (C) MT1A/2A expression was analyzed by immunoblot. Gene expression of MTs was analyzed by
q-RT-PCR and immunoblot after 10 days. Statistical analysis was performed by one-way ANOVA test followed by Bonferroni correction. A value of p < 0.05 was
considered significant. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. (D) Calcium content of solubilized ECM is presented in MT1A/B knocked down cells. Data are
expressed as mean ± SEM of three independent experiments. Statistical analysis was performed by one-way ANOVA test followed by Bonferroni correction. A value
of p < 0.05 was considered significant. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
Pi-induced phenotypic switch of VSMCs by further repressing
VSMCs marker genes and upregulating osteochondrogenic
genes; (3) PHI FG4592 exacerbates VSMCs mineralization;
(4) PHI FG4592 influences Ser451 phosphorylation of Runx2
and increases PDK4 expression in response to high Pi; (5) zinc
inhibits osteochondrogenic reprogramming and mineralization
of VSMCs in response to PHI FG4592 and high Pi; and (6) zinc
plasma levels are significantly lower in CKD and in patients
underwent carotid endarterectomy compared to healthy controls.
A novel therapeutic approach to correct CKD-associated
anemia is the induction of EPO synthesis by stabilizing hypoxia-
inducible factors (HIFs) with prolyl hydroxylase inhibitors
(PHIs). PHIs are all promising candidates with great therapeutic
potential for improving anemia in CKD (Carney, 2016;
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FIGURE 8 | Plasma zinc level is reduced in patients undergoing carotid
endarterectomy and in CKD patients on hemodialysis. Healthy volunteers
without any known diseases (n = 18, mean age 46 years, F/M 7/11), Stage 5
CKD patients subjected to hemodialysis (n = 28, mean age 55 years, F/M
15/13), and patients undergoing carotid endarterectomy (n = 15, mean age
72 years, F/M 6/9) were recruited and plasma zinc levels were measured with
inductively coupled plasma-atomic emission spectrometry (ICP-AES).
Statistical analysis was performed by one-way ANOVA test followed by
Bonferroni correction. A value of p < 0.05 was considered significant.
∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
Gupta and Wish, 2017). However, recent reports have shown
that HIFs accelerate vascular calcification (Mokas et al., 2016;
Zhu et al., 2018), one of the major risk factors for morbidity
and mortality in CKD (Sigrist et al., 2007; Collins et al., 2015;
Schlieper et al., 2016) due to hyperphosphatemia (Hruska et al.,
2008). Therefore, we investigated whether HIF PHI FG4592
triggers the osteochondrogenic differentiation of VSMCs in
response to high Pi.
Growing evidence suggests that hypoxia and HIFs play a
vital role in vascular calcification, and targeting HIF blocks
mineralization in hypoxia (Mokas et al., 2016; Balogh et al.,
2019). Our results presented here support the link between
HIFs and vascular calcification. We demonstrate that the
pharmacologic stabilization of HIFs by PHI aggravates high Pi-
induced mineralization of VSMCs, which indicates that PHIs,
due to their HIF-stabilizing effect, might accelerate vascular
calcification in CKD.
Another link between HIFs and vascular calcification has
recently been suggested by Zhu et al. (2018). This study
demonstrates that the stabilization and nuclear translocation of
HIF accelerate VSMC calcification via PDK4 in VSMCs, while
inhibition of PDK4 attenuates mineralization. Others have shown
that PDK4 expression is increased in calcifying VSMCs as well as
in the vessel walls of patients suffering from vascular calcification
(Lee et al., 2015). Our data demonstrate that the stabilization of
HIFs by PHI also induces PDK4 expression, which is likely to be
involved in the accelerated calcification of VSMCs in response to
high Pi and PHI FG4592.
FIGURE 9 | Zinc protects against phosphate- and HIF-prolyl hydroxylase
inhibitor-induced vascular smooth muscle cell calcification. PHI FG4592
aggravates vascular calcification by increasing phosphate (Pi) uptake and
calcium deposition by VSMCs, lowering smooth muscle-specific gene
expression (ACTA-2 [smooth muscle alpha (α)-2 actin], MYH11 [smooth
muscle myosin heavy chain 11], and TAGLN ([smooth muscle protein 22-α],
increasing osteochondrogenic gene expression (BMP-2 [bone morphogenic
protein-2], Msx-2 [Msh Homeobox 2], and SP7), inducing pyruvate
dehydrogenase kinase 4 (PDK4), decreasing the phosphorylation level of
Runx2 Ser451, and lowering cell viability. Importantly, zinc inhibits PHI
FG4592-aggravated calcification by high Pi via maintaining VSMC phenotype,
decreasing Pi uptake, lowering osteochondrogenic gene expression and the
level of PDK4 as well as preserving Runx2 Ser451 phosphorylation and cell
viability.
Osteochondrogenic reprogramming of VSMCs is a typical
phenomenon during mineralization. Elevated extracellular Pi
induces phenotypic switch of VSMCs into osteoblast-like cells
enhancing vascular calcification by reducing the expression of
VSMC markers (smooth muscle 22α, SM22α; smooth muscle
alpha-actin, SM α-actin) and up-regulating osteoblast-specific
genes (Steitz et al., 2001). In line with these observations, we
confirmed that high extracellular Pi induces osteochondrogenic
genes and down-regulates smooth muscle markers. A recent
report has shown that HIF-1α triggers phenotypic switch in
VSMCs by down-regulating smooth muscle cell-specific genes
(Liu et al., 2017). Similar to this report, here we show that by
stabilizing HIF, PHI FG4592 down-regulates smooth muscle-
specific gene expression. Importantly, this effect was also
observed at the physiological Pi level. This is in agreement
with the finding of Nishide et al. (2019) who have shown
that PHI FG4592 can alter the phenotype of tumor-infiltrating
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macrophages. Our results also demonstrate that high Pi and PHI
FG4592 synergistically lower SMC-specific gene levels in VSMCs
suggesting that CKD patients might be at greater risk to develop
vascular calcification in response to PHI FG4592 therapy due to
their elevated Pi levels.
Osteochondrogenic transformation of VSMCs also involves
proteins regulating osteoblast development in bones play a
pivotal role in the osteoblastic transformation and calcification
of VSMCs. BMP-2 is commonly expressed in calcified human
atherosclerotic plaques (Boström et al., 1993) and dose-
dependently triggers phosphate-induced calcification in human
VSMC (Li et al., 2008). It has been reported that hypoxia
induces BMP-2 expression in osteoblasts (Tseng et al., 2010)
and microvascular endothelial cells (Bouletreau et al., 2002). Our
data presented here demonstrate that PHI FG4592 exacerbates
Pi-induced expression of osteochondrogenic genes such as BMP-
2, Msx-2, and Sp7. Our findings are in good agreement with
other studies demonstrating that hypoxia increases osteogenic
gene expression in mesenchymal stem cells (Ding et al., 2014)
and periosteal cells (Ichijima et al., 2012) which suggest this
mode of action by which PHI FG4592 enhances Pi-induced
calcification of VSMCs. Interestingly, PHI FG4592 at physiologic
Pi level does not induce osteochondrogenic gene expression
suggesting that PHIs do not accelerate vascular calcification at the
normal Pi level.
Runx2-dependent activation of osteochondrogenic gene
expression is affected by the post-transcriptional modifications
of Runx2 (Wee et al., 2002; Ge et al., 2009; Li et al.,
2017). Phosphorylation of different serine (S) residues greatly
affects its transactivation properties and ubiquitin-dependent
degradation. S451 phosphorylation could act to downregulate
Runx2-dependent transactivation (Wee et al., 2002). Here we
show that PHI FG4592 decreases the phosphorylation of S451
in VSMCs in response Pi. However, phosphorylation of S451 is
not influenced by the calcification medium alone. This suggests
that the decreased phosphorylation level of Runx2 S451 might
be involved in the more rapid and extensive calcification as well
as the robust induction in osteochondrogenic genes provoked
by PHI FG4592 compared to high Pi alone. Importantly, zinc
restores the phosphorylation level of Runx2 Ser451 that might
be a possible mechanistic mode of action by which zinc inhibits
osteochondrogenic gene activation by Runx2.
Recent reports have shown that zinc attenuates vascular
calcification (Shin and Kwun, 2014; Voelkl et al., 2018) by
restoring VSMC viability (Shin and Kwun, 2014). Our results
support the protective effect of zinc in vascular calcification by
enhancing VSMC viability in response to PHI and high Pi.
Evidence suggests that ROS and oxidative stress are involved
in the pathogenesis of vascular calcification (Byon et al.,
2008; Agharazii et al., 2015) that is effectively ameliorated
by zinc supplementation in vitro (Shin and Kwun, 2013,
2014, 2016; Voelkl et al., 2018). One tenable hypothesis is
that zinc may induce ROS scavenger proteins which are able
to reduce calcification by scavenging ROS. Metallothioneins
(MTs) are abundantly induced by high levels of zinc and
cadmium (Hamer, 1986) and characterized by potent antioxidant
properties (Viarengo et al., 2000). In addition, VSMCs in
atherosclerotic plaques express MTs which act as scavengers for
ROS (Göbel et al., 2000), but this has not been experimentally
tested so far. Here we show that MTs are not involved in the
protective effect of zinc against vascular calcification, and other
mechanisms than MTs are responsible for the protective effect of
zinc supplementation.
This link between zinc and vascular diseases is also suggested
by Voelkl et al. who has shown that low zinc level might be
associated with increased calcification in CKD (Voelkl et al.,
2018). In accordance with this study, we detect low plasma
zinc levels in dialysis dependent-CKD patients compared to
healthy controls. Similar to the observations in CKD, patients
who underwent carotid endarterectomy present also reduced
zinc plasma levels compared to healthy controls. Our data
suggest that low plasma zinc level is associated with vascular
calcification not only in CKD but also in patients diagnosed with
significant carotid artery stenosis. This phenomenon underlines
the importance of monitoring and maintaining physiological
plasma zinc levels in patients with increased risk for vascular
calcification (Chen and Moe, 2012; Chen et al., 2017).
Here we demonstrate that PHI FG4592 is a potent inducer of
osteogenic differentiation of VSMCs in elevated Pi environments.
Zinc has the capability to prevent PHI FG4592 induced
mineralization of VSMCs and osteogenic gene induction in high
Pi media. The beneficial role of zinc in Pi-mediated calcification
has been suggested by other studies as well (Shin and Kwun,
2016; Voelkl et al., 2018). Our results described here showed that
PHI FG4592, a promising candidate for correcting anemia in
CKD, markedly exacerbates Pi-induced calcification of VSMCs.
PHI FG4592 promotes vascular calcification by increasing Pi
uptake and calcium deposition by VSMCs, triggering their
phenotypic reprogramming, inducing PDK4, and modulating
the phosphorylation level of Runx2. Importantly, zinc attenuates
PHI FG4592-promoted calcification by high Pi (Figure 9).
These observations suggest that (1) extended follow-up period
should be implicated in clinical trials with CKD patients using
PHIs; (2) the pro-calcification effect of other PHIs should
also be tested; and (3) zinc plasma levels should be closely
monitored parallel with EPO and hemoglobin levels in patients
during the administration FG4592 or other PHIs, and zinc
supplementation might be considered. In addition, our data
suggest that low plasma zinc level might be an independent risk
factor for developing vascular calcification independently from
renal disease. This necessitates the screening of plasma zinc levels
in susceptible patients to reduce the risk for vascular calcification.
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